Inventor
CALZONE FRANK J
US22 patents
⚠️ This page may combine multiple inventors who share the name “CALZONE FRANK J”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
AMGEN INC
13 patentsUS6284485B1Sep 4, 2001
Nucleic acids encoding osteoprotegerin
AMGEN INC123 citations98
US6015938AJan 18, 2000
Osteoprotegerin
AMGEN INC158 citations98
US7871611B2Jan 18, 2011
Compositions and methods relating to anti IGF-1 receptor antibodies
AMGEN INC46 citations96
US6369027B1Apr 9, 2002
Osteoprotegerin
AMGEN INC65 citations96
US6288032B1Sep 11, 2001
Osteoprotegerin
AMGEN INC56 citations96
US6284728B1Sep 4, 2001
Osteoprotegerin
AMGEN INC57 citations96
US6284740B1Sep 4, 2001
Osteoprotegerin
AMGEN INC56 citations96
US6613544B1Sep 2, 2003
Osteoprotegerin
AMGEN INC20 citations92
US7005413B1Feb 28, 2006
Combination therapy for conditions leading to bone loss
AMGEN INC16 citations82
US8895008B2Nov 25, 2014
Compositions and methods relating to anti-IGF-1 receptor antibodies
AMGEN INC1 citations61
US7632922B1Dec 15, 2009
Osteoprotegerin
AMGEN INC1 citations52
US10035861B2Jul 31, 2018
Compositions and methods relating to anti-IGF-1 receptor antibodies
AMGEN INC0 citations51
US11078288B2Aug 3, 2021
Methods and compositions for treating tumor diseases
AMGEN INC0 citations41
REMD BIOTHERAPEUTICS INC
6 patentsUS11319372B2May 3, 2022
Cancer treatment using antibodies that bind cytotoxic T-lymphocyte antigen-4 (CTLA-4)
REMD BIOTHERAPEUTICS INC3 citations72
US11629184B2Apr 18, 2023
Calcitonin gene-related peptide (CGRP) antagonist antibodies
REMD BIOTHERAPEUTICS INC0 citations62
US11332531B2May 17, 2022
Immunotherapy using antibodies that bind programmed death ligand-1 (PD-L1)
REMD BIOTHERAPEUTICS INC0 citations62
US11319376B2May 3, 2022
Combination of glucagon receptor antagonists and PI3K pathway inhibitors for the treatment of cancer
REMD BIOTHERAPEUTICS INC0 citations62
US11248049B2Feb 15, 2022
Immunotherapy using antibodies that bind Programmed Death 1 (PD-1)
REMD BIOTHERAPEUTICS INC0 citations62
US11242398B2Feb 8, 2022
Anti-OX40 antibodies and methods of activating OX40
REMD BIOTHERAPEUTICS INC0 citations51